My ePortfolio Register   

The more the T-lymphocytes differ, the more effectively they fight against leukaemia

Adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (r/r ALL) have a poor prognosis despite intense salvage treatments.

Recent reports have shown that Blinatumomab (Blin) can induce high remission rates in these patients.

Blin is a bispecific T-cell engager antibody construct that is designed to direct cytotoxic T cells to CD19-expressing B cells.

T-cell receptors (TR) which are present on the surface of T-lymphocytes are necessary for recognition of pathogens.

The extremely high diversity (up to 120 million different TRβ gene rearrangements in young individuals) of TR enables protection against the great variety of pathogens.

We investigated the TRβ repertoire in patients on Blin treatment using next generation sequencing (NGS).

NGS is a revolutionary technology enabling the assessment of TR characteristics with very high resolution.

We compared the diversity of TRβ repertoire in r/r ALL patients responding and non-responding to Blin salvage treatment.

The repertoire before Blin administration was significantly (=probably caused by something other than mere chance) more diverse in Blin responders compared to non- responders.

Also the increase of the repertoire diversity during Blin treatment was sharper and significant in responders, whereas non-significant in non-responders.

Further studies on larger patient cohorts are necessary to confirm this observation and to show whether response to Blin can be predicted by TRβ repertoire diversity before treatment.

Source: EHA

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence